Drug Specific Side Effect and Monitoring Pages for Targeted Therapies FAQs
Author: Dr. Sarah Mitchell
On September 3, 2026, targeted oncology groups published patient counseling FAQs for side effect monitoring during kinase inhibitor therapies. Kinase inhibitors and targeted biologicals require strict blood chemistry and lab monitoring schedules to manage class-specific toxicities.
At Onco Medicine, we support patient safety by providing manufacturer patient guides and Certificate of Analysis batch documents for imported therapies.
Frequently Asked Questions
Key side effects and monitoring guidelines for common targeted classes:
- Q: What monitoring is required for FGFR inhibitors (e.g. Infigratinib)?
A: Regular serum phosphate testing is required due to hyperphosphatemia risk, alongside periodic eye exams to monitor for retinal changes. - Q: How do we manage EGFR inhibitor side effects (e.g. Osimertinib)?
A: Regular ECG monitoring is recommended to screen for QTc prolongation, alongside monitoring for hand-foot syndrome or diarrhea.
Chat with our pharmacist on WhatsApp +91 94275 19809 or email us at support@onco-medicine.com.
